07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

MCB3837 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to MCB3837 from Biovertis’ Morphochem AG subsidiary to treat Clostridium difficile infection (CDI). MCB3837 is a water-soluble, IV prodrug of Morphochem’s MCB3681, a small...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Company News

ProBioGen management update

ProBioGen AG , Berlin, Germany   Business: Gene/Cell therapy   Hired: Gertraud Unterrainer as CFO, formerly CFO of Biovertis AG  ...
07:00 , Sep 11, 2006 |  BC Week In Review  |  Clinical News

Oxaquin: Phase I start

This month, Biovertis will start a dose-escalation, German Phase I trial in 24 healthy volunteers. Biovertis AG , Vienna, Austria   Product: Oxaquin   Business: Infectious   Molecular target: NA   Description: Antibiotic agent  ...
07:00 , Aug 28, 2006 |  BC Week In Review  |  Company News

4-Antibody management update

4-Antibody AG , Munich, Germany   Business: Antibodies   Hired: Sijmen de Vries as CEO, formerly CEO of Biovertis AG 's Morphochem AG unit; he replaces Ulf Grawunder, who will become CSO  ...
00:27 , Aug 22, 2006 |  BC Extra  |  Company News

4-Antibody names CEO, raises $4.9M

4-Antibody (Basel, Switzerland) hired Sijmen de Vries as CEO. He replaces co-founder Ulf Grawunder, who will become CSO. Previously, de Vries was CEO of Morphochem , which was acquired by Biovertis (Vienna, Austria) last year....
07:00 , May 22, 2006 |  BC Week In Review  |  Company News

Biovertis management update

Biovertis AG , Vienna, Austria   Business: Infectious   Hired: Thomas Kapsner as COO, formerly acting managing director of European operations for Argos Therapeutics Inc.  ...
01:27 , May 19, 2006 |  BC Extra  |  Company News

Biovertis names Kapsner COO

Infectious disease company Biovertis (Vienna, Austria) hired Thomas Kapsner as COO. Most recently, he was acting managing director of European operations for Argos (Durham, N.C.)....
08:00 , Feb 13, 2006 |  BioCentury  |  Strategy

Spin once; spin again

It is not unusual for European biotech companies to do spinouts, generally to unwind dual therapeutics/service businesses. It is less common for a company to have a technology platform sufficiently productive to generate several potential...
08:00 , Dec 19, 2005 |  BioCentury  |  Tools & Techniques

Clipping Alzheimer's at the start

Efforts to treat the underlying causes of Alzheimer's disease have shifted from trying to dissolve plaques toward slowing down formation of beta amyloid , which is believed to be crucial for disease progression. However, Probiodrug...